The investigation centers on the fairness of the deal terms currently presented to investors of the NASDAQ-listed biotech company. Attorney Juan Monteverde, whose firm is recognized in the 2025 ISS Securities Class Action Services Report, is spearheading the review from their Empire State Building headquarters. Shareholders are being encouraged to evaluate the offer closely, as the firm aims to identify potential discrepancies in the valuation process.

Investors holding common stock in Pacira BioSciences can contact the firm to discuss their rights or to obtain further details regarding the ongoing review. Monteverde & Associates, which maintains a track record in trial and appellate courts, is offering consultations at no cost to those concerned about the impact of the Viatris transaction on their holdings.